September 2003
Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p2
Trade Publication
Reports on the approval received by Medicure Inc. from the Therapeutic Products Directorate in Canada to commence a Phase II hypertension trial as part of the development program for the second clinical candidate of the company, MC-4232.


Related Articles

  • Late-stage hypertension drugs show promise. Belden, Heidi // Drug Topics;9/17/2007, Vol. 151 Issue 18, p46 

    The article discusses developments in antihypertensive agents in the U.S. Novartis' oral renin inhibitor aliskiren had been approved by the Food and Drug Administration (FDA) to treat hypertension (HTN) in March 2007. It blocks the action of renin at the top of the renin-angiotensin system...

  • MEDICURE GETS FDA/TPD APPROVALS FOR MC-1 PHASE II TRIAL.  // Worldwide Biotech;Jan2004, Vol. 16 Issue 1, p1 

    States that Medicure Inc., a Winnipeg, Manitoba-based cardiovascular drug company, has received approval from the United States Food and Drug Administration and the Canadian Therapeutic Product Directorate to initiate its Phase II clinical study to treat patients with the company's MC-1 drug.

  • Medicure annual net loss decreases.  // PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p17 

    The article reports that the net loss of Medicure Inc. for year ending May 31, 2011 has decreased compared to its net loss for year ending in May 31, 2010.

  • MEDICURE EXPANDS INTELLECTUAL PROPERTY POSITION.  // Worldwide Biotech;Dec2002, Vol. 14 Issue 12, p4 

    Reports on a patent issued to cardiovascular drug discovery and development company Medicure Inc. by the U.S. Patent Office to protect the composition of several of the company's newly discovered therapeutics, as of December 2002.

  • MEDICURE GETS PATENT NOTICE OF ALLOWANCE FOR THERAPEUTICS.  // Worldwide Biotech;Sep2002, Vol. 14 Issue 9, p5 

    Reports on the Notice of Allowance received by Medicure Inc. from the U.S. Patent Office for a composition of matter patent covering several of the company's discovered therapeutics for use in treatment of cardiovascular diseases.

  • Financings Roundup.  // BioWorld Today;3/2/2010, Vol. 21 Issue 40, p3 

    The article reports on an agreement by Medicure Inc. with the lender under its secured debt financing agreement of September 17, 2007, to further defer required payments of about 2.1 million U.S. dollars until March 14, 2010.

  • Medicure reports annual net income.  // PharmaWatch: CNS;Nov2012, Vol. 11 Issue 11, p22 

    The article reports on the financial results of specialty pharmaceutical firm Medicure Inc. in its fiscal year ending May 31, 2012, including a net income of 23.38 million Canadian dollar against a net loss of 1.63 million Canadian dollar in the year ending March 31, 2011.

  • Financings Roundup.  // BioWorld Today;10/3/2007, Vol. 18 Issue 192, p7 

    The article reports on the $16 million gross proceeds raised by Winnipeg, Manitoba-based Medicure Inc. through a private placement. The proceeds exceeded the $1 million target. The company issued a total of 13.91 million common shares at a price of $1.15, together with warrants to purchase 4.17...

  • Medicure Raises $40M To Advance Cardio Drugs.  // Bioworld Week;8/27/2007, Vol. 15 Issue 35, p3 

    The article reports on the signing of agreement between Medicure Inc. and Manchester Securities Corp. to raise $40 million funds in the U.S. It notes that it is dedicated in furthering an ongoing clinical development of a new cardioprotective agent and the commercialization efforts for an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics